Daily Archives: February 20, 2022
CELLULAR AND MOLECULAR IMPACT OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE (DSS)-INDUCED COLITIS IN RATS
The melanocortin 1 receptor (MC1r)–specific agonist PL8177 and its main metabolite PL8435 have demonstrated MC1r binding affinity and functional activity that mirrors that of α-melanocyte stimulating hormone (a-MSH). a-MSH has been demonstrated to be e… Continue reading
Posted in News
Comments Off on CELLULAR AND MOLECULAR IMPACT OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE (DSS)-INDUCED COLITIS IN RATS
CROHN’S DISEASE COMPLICATED BY ILEOSIGMOID FISTULA: ASSESSMENT AND MANAGEMENT UPDATE
The preoperative evaluation of Crohn’s-related ileosigmoid fistula (ISF) is complex with multiple preoperative diagnostic modalities available. Intraoperative management is also complicated when deciding whether to repair the fistula or resect the invo… Continue reading
Posted in News
Comments Off on CROHN’S DISEASE COMPLICATED BY ILEOSIGMOID FISTULA: ASSESSMENT AND MANAGEMENT UPDATE
DISCOVERY OF IBD3540: A NOVEL GUT-RESTRICTED GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR WITH ORAL ACTIVITY IN MOUSE COLITIS MODELS
Glutamate carboxypeptidase II (GCPII) is robustly overexpressed in both Crohn’s disease and ulcerative colitis and is a promising therapeutic target for IBD. We have previously published that systemically or enema administered small molecule GCPII inhi… Continue reading
Posted in News
Comments Off on DISCOVERY OF IBD3540: A NOVEL GUT-RESTRICTED GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR WITH ORAL ACTIVITY IN MOUSE COLITIS MODELS
CONCORDANCE BETWEEN REMISSION DEFINED BY PATIENTS VS PATIENT-REPORTED OUTCOME MEASURES IN INFLAMMATORY BOWEL DISEASE
Although validated patient-reported outcome measurements (PRO) can categorize patients with inflammatory bowel disease (IBD) into remission or active disease, patients may have different definitions of remission. Patients may assume a new normal with a… Continue reading
Posted in News
Comments Off on CONCORDANCE BETWEEN REMISSION DEFINED BY PATIENTS VS PATIENT-REPORTED OUTCOME MEASURES IN INFLAMMATORY BOWEL DISEASE
LACTOCOCCUS LACTIS DELIVERY OF SURFACE LAYER PROTEIN A PROTECTS MICE FROM COLITIS BY RE-SETTING HOST IMMUNE REPERTOIRE
Inflammatory bowel disease (IBD) is characterized by gastrointestinal inflammation comprised of Crohn’s disease and ulcerative colitis. Centers for Disease Control and Prevention report that 1.3% of the population of the United States (approximately 3 … Continue reading
Posted in News
Comments Off on LACTOCOCCUS LACTIS DELIVERY OF SURFACE LAYER PROTEIN A PROTECTS MICE FROM COLITIS BY RE-SETTING HOST IMMUNE REPERTOIRE
COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Moderate-to-severe ulcerative colitis (UC) is associated with burden on quality of life (Kawalec, 2016). The Communicating Needs and Features of IBD Experiences (CONFIDE) study aims to increase understanding of patients’ experiences and the impact of I… Continue reading
Posted in News
Comments Off on COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
ORAL ADMINISTRATION OF NANOLIPOSOMES LOADED M13 MAY TREAT ULCERATIVE COLITIS AND COLITIS-ASSOCIATED CANCER WITHOUT CAUSING ANY SIDE EFFECTS
Intestinal inflammation, especially chronic (such as inflammatory bowel disease [IBD]), is an indispensable participant in the colonic neoplastic process, fostering the proliferation, survival, and migration of colonic tumor cells. Molecularly targeted… Continue reading
Posted in News
Comments Off on ORAL ADMINISTRATION OF NANOLIPOSOMES LOADED M13 MAY TREAT ULCERATIVE COLITIS AND COLITIS-ASSOCIATED CANCER WITHOUT CAUSING ANY SIDE EFFECTS
UHPLC-MS/MS-BASED PLASMA LIPIDOMICS REVEAL ALTERATIONS ASSOCIATED WITH EXCLUSIVE ENTERAL NUTRITION TREATMENT IN ADULT PATIENTS WITH ACTIVE CROHN’S DISEASE
Exclusive enteral nutrition (EEN) is an effective treatment for active Crohn’s disease (CD), although the mechanisms is unclear. Lipid metabolism and signaling have been suggested to play an important role in the pathophysiology of the disease, but the… Continue reading
Posted in News
Comments Off on UHPLC-MS/MS-BASED PLASMA LIPIDOMICS REVEAL ALTERATIONS ASSOCIATED WITH EXCLUSIVE ENTERAL NUTRITION TREATMENT IN ADULT PATIENTS WITH ACTIVE CROHN’S DISEASE
ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY
Following inadequate response, loss of response, or intolerance to a first-line biologic, patients with Crohn’s disease (CD) may switch treatment to a second-line biologic therapy. Data on the clinical outcomes of patients receiving two or more lines o… Continue reading
Posted in News
Comments Off on ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY
RELATIONSHIP BETWEEN SELF-REPORTED SLEEP AND DISEASE ACTIVITY DIFFERS BASED ON ENDOSCOPIC OR CLINICAL DISEASE ACTIVITY MEASURES
Patients with inflammatory bowel disease (IBD) report more sleep disturbances than healthy controls. Self-reported sleep disturbances have been associated with active clinical disease. Few studies have examined the relationship between self-reported sl… Continue reading
Posted in News
Comments Off on RELATIONSHIP BETWEEN SELF-REPORTED SLEEP AND DISEASE ACTIVITY DIFFERS BASED ON ENDOSCOPIC OR CLINICAL DISEASE ACTIVITY MEASURES